ArticleClinical and experimental medicine2025
Dual-targeted therapy for the management of refractory Crohn's disease: a retrospective cohort study.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
- The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Crohn's disease (CD) is a chronic relapsing autoimmune disease. Dual-targeted therapy (DTT) has been proven effective and safe in refractory inflammatory bowel disease (IBD), especially the combination of ustekinumab with vedolizumab (UST + VDZ). However, the efficacy and safety of DTT on refractory CD are still limited or insufficient. We aim to evaluate the efficacy and safety of DTT including ustekinumab combined with adalimumab (UST + ADA) and UST + VDZ in refractory CD patients. Refractory CD patients who failed at least two biologics from Xijing IBD Center were included. Clinical evaluation was performed by Crohn's Disease Activity Index (CDAI). Endoscopic data were assessed using Simple Endoscopic Score-Crohn's Disease (SES-CD). Other clinical indicators were also collected. Totally, 23 patients were enrolled, and 20 completed 4-27 months of follow-up. Among these patients, there were significant post-treatment reductions in median SES-CD [14.5-5 (p < 0.005)] and CDAI [326.25-94.75 (p < 0.005)]. For UST + ADA (n = 16), 68.75% reached endoscopic response, 56.25% achieved endoscopic remission, 75% clinical response occurred, and 68.75% of patients achieved clinical remission. For UST + VDZ (n = 4), 25% had endoscopic response, 50% had clinical response, and one achieved clinical remission. The regimen of UST + ADA exhibited a more favorable performance during follow-up. 7 patients discontinued DTT due to no significant improvement or exacerbation, and no severe adverse events were observed. The study supports the effectiveness and safety of DTT for refractory CD and especially suggests the potential efficacy and safety of UST + ADA. Larger sample and randomized controlled trial (RCT) studies are needed for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.